

Eprontia - (25 mg/mL; Oral Solution)

Generic Name	Topiramate	Innovator	Cutis (Azurity)
Dosage	25 mg/mL; Oral Solution	Branded US Sales	Less Than \$1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	None	Tentative Approvals	None
Final Approvals	Less Than 5	Generic Launches	None
Indication	EPRONTIA is indicated for: 1) Epilepsy: Initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older; adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with LennoxGastaut syndrome in patients 2 years of age and older. 2) Preventive treatment of migraine in patients 12 years of age and older.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact <u>contact@researchdelta.com</u> to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.